Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03.
Saved in:
| Title: | Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03. |
|---|---|
| Authors: | Saura, C.1 (AUTHOR) csaura@vhio.net, Cortés, J.2,3,4,5,6 (AUTHOR), Modi, S.7 (AUTHOR), Kim, S.-B.8 (AUTHOR), Hamilton, E.9 (AUTHOR), Hurvitz, S.A.10 (AUTHOR), Krop, I.E.11 (AUTHOR), Curigliano, G.12,13 (AUTHOR), Iwata, H.14 (AUTHOR), Im, S.-A.15 (AUTHOR), Herbolsheimer, P.16 (AUTHOR), Karnoub, M.17 (AUTHOR), Boran, A.17 (AUTHOR), Kuwahara, Y.17 (AUTHOR), Egorov, A.17 (AUTHOR), André, F.18 (AUTHOR) |
| Source: | Annals of Oncology. Mar2026, Vol. 37 Issue 3, p353-363. 11p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.11.007 |
